Influenza Vaccination in Patients with Egg Allergy

Current Evidence-Based Approach

The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommends that any licensed, age-appropriate influenza vaccine, including egg-based vaccines like Influvac Tetra, may be administered to persons with egg allergy of any severity 1, 2
For patients with mild egg allergy, the CDC recommends administering any age-appropriate influenza vaccine in the standard manner, with no skin testing required, no divided-dose protocols needed, and a standard 15-minute post-vaccination observation period 1, 2, 3
For patients with severe egg allergy reactions, the CDC recommends that any age-appropriate influenza vaccine can still be used, including egg-based vaccines, but must be administered in an inpatient or outpatient medical setting with supervision by a healthcare provider capable of recognizing and managing severe allergic reactions 1, 2, 3

The Recombinant Influenza Vaccine (RIV4) is a completely egg-free alternative, approved for ages ≥18 years 2, 3
The Cell Culture-Based Vaccine (ccIIV4) contains a theoretical maximum of 1.7×10⁻⁸ μg/0.5 mL egg protein, approved for ages ≥2 years 2, 3

The American Academy of Pediatrics and the CDC advise against unnecessarily delaying or withholding vaccination due to egg allergy concerns 2, 3
The CDC recommends against performing skin testing with the vaccine before administration 2, 3
The CDC advises against using divided-dose protocols for egg-allergic patients 3, 5

The only absolute contraindication to influenza vaccination is a previous severe allergic reaction to the influenza vaccine itself, regardless of which component was responsible 1, 4

The CDC requires all vaccination providers to be familiar with their office emergency plan and certified in cardiopulmonary resuscitation 2, 4